Enrolling Now
ESK-001 for Moderate to Severe Plaque Psoriasis Study in Kentucky (ONWARD1)
ENROLLING — This clinical trial will evaluate the effectiveness of ESK-001 in treating moderate to severe plaque psoriasis.
Ruxolitinib Cream Study for Pediatric Nonsegmental Vitiligo in Kentucky
ENROLLING — This study evaluates the safety and efficacy of Ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
APG777 for Moderate to Severe Atopic Dermatitis Study in Kentucky
ENROLLING — This two-part study will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
Tildrakizumab for Moderate to Severe Genital Psoriasis Study in Kentucky
ENROLLING — Phase 3 study to evaluate the efficacy and safety of subcutaneous Tildrakizumab in subjects with moderate to severe genital psoriasis.
Upadacitinib for Moderate to Severe Hidradenitis Suppurativa Study in Kentucky
ENROLLING — This study will assess how safe and effective Upadacitinib is in treating adult and adolescent participants with moderate to severe HS.
Eltrekibart Study for Moderate to Severe Hidradenitis Suppurativa in Kentucky
ENROLLING — Be part of a clinical study in Kentucky evaluating the safety and efficacy of Eltrekibart for adults with moderate to severe Hidradenitis Suppurativa.
Ixekizumab and Tirzepatide for Plaque Psoriasis and Overweight Study in Kentucky
ENROLLING — Join our Kentucky study to explore the effects of Ixekizumab and Tirzepatide on individuals with plaque psoriasis and overweight.
Lutikizumab Study for Moderate to Severe Hidradenitis Suppurativa in Kentucky
ENROLLING — Participate in a clinical trial in Kentucky evaluating the safety and efficacy of Lutikizumab for adults and adolescents with moderate to severe Hidradenitis Suppurativa.
Rinvoq vs. Dupixent for Children Atopic Dermatitis Study in Kentucky
ENROLLING — Join our Phase 3 study in Kentucky comparing Upadacitinib and Dupilumab for children 6 to under 12 with moderate to severe atopic dermatitis.
Coming Soon
Amlitelimab in Moderate-to-Severe Atopic Dermatitis Trial in Kentucky
Explore Amlitelimab, an innovative treatment for Atopic Dermatitis, in our COAST 2 clinical trial located in Kentucky.
